Top Medical News
4 days ago
Moderate-intensity aerobic and resistance exercises may not be enough to attenuate the negative effects of androgen deprivation therapy (ADT) on metabolic markers and bone mineral density in older men with prostate cancer, a recent study has found.
6 days ago
Coadministration of DHA and vitamin E supplements results in increased sperm motility, but no significant changes have been observed in sperm morphology and vitality in asthenozoospermic men, a study has shown.
6 days ago
In the treatment of multiple sclerosis (MS) patients with overactive bladder (OAB), mirabegron and solifenacin yield similar response rates, with the latter producing a greater decrease in urinary symptom severity but exerting a less favourable effect on constipation, a study has found.
6 days ago
Lower urinary tract syndrome (LUTS), urinary incontinence, and coital incontinence all worsen sexual function and quality of life in older women, a recent study has found.
16 Sep 2020
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
Stephen Padilla, 15 Sep 2020
Tobacco smoking exposure appears to result in lower neoadjuvant chemotherapy response rates as well as higher overall and cancer-specific mortality, according to a systematic review and meta-analysis. Smoking status is also associated with bladder cancer recurrence after radical cystectomy.
15 Sep 2020
Men with neurogenic bladder (NGB) are at higher risk of complications after placement of implantable penile prostheses (IPPs), a recent study has shown.
Special Reports
26 Nov 2019
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
15 Mar 2019
At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.
Conference Reports
Audrey Abella, 23 Mar 2020
The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).
Elaine Soliven, 14 Mar 2020
The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU 2020.
Pearl Toh, 09 Mar 2020
A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS 2020.
Roshini Claire Anthony, 05 Mar 2020

Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.

Audrey Abella, 03 Mar 2020
An electronic surveillance tool generated better compliance and satisfaction rates than standard in-person care among men with stage 1 testicular cancer, according to the interim results of the WATChmAN* trial presented at ASCO GU 2020.
Pearl Toh, 02 Mar 2020
While combining docetaxel with androgen deprivation therapy (ADT) is known to improve survival for advanced prostate cancer, its role in the setting of adjuvant treatment given after radical radiotherapy plus ADT for the treatment of intermediate- and high-risk prostate cancer was proven otherwise — both in terms of biochemical disease-free survival (BDFS) and quality of life (QoL), according to the SPCG*-13 trial presented at the 2020 Genitourinary Cancer Symposium (GUCS).
Roshini Claire Anthony, 29 Feb 2020

The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.